Cetuximab retreatment in patients with metastatic colorectal cancer who exhibited a clinical benefit in response to prior cetuximab: A retrospective study.

Tanioka, Hiroaki; Asano, Motoi; Yoshida, Ryousuke; Waki, Naohisa; Uno, Futoshi; Ishizaki, Masahiro; Yamashita, Kazuki; Morishita, Yuki; Nagasaka, Takeshi

Tanioka, Hiroaki; Asano, Motoi; Yoshida, Ryousuke; Waki, Naohisa; Uno, Futoshi; Ishizaki, Masahiro; Yamashita, Kazuki; Morishita, Yuki; Nagasaka, Takeshi.

Afiliación

Tanioka H; Department of Medical Oncology, Okayama Rosai Hospital, Okayama 702-8055, Japan.
Asano M; Department of Clinical Oncology, Kawasaki Medical School Hospital, Okayama 701-0192, Japan.
Yoshida R; Department of Medical Oncology, Okayama Rosai Hospital, Okayama 702-8055, Japan.
Waki N; Department of Surgery, Okayama Rosai Hospital, Okayama 702-8055, Japan.
Uno F; Department of Surgery, Okayama Rosai Hospital, Okayama 702-8055, Japan.
Ishizaki M; Department of Surgery, Okayama Rosai Hospital, Okayama 702-8055, Japan.
Yamashita K; Department of Surgery, Okayama Rosai Hospital, Okayama 702-8055, Japan.
Morishita Y; Department of Surgery, Okayama Rosai Hospital, Okayama 702-8055, Japan.
Nagasaka T; Department of Pharmacy, Okayama Rosai Hospital, Okayama 702-8055, Japan.

Oncol Lett ; 16(3): 3674-3680, 2018 Sep.

Article en En | MEDLINE | ID: mdl-30127977

Palabras clave

cetuximab; colorectal cancer; irinotecan; re-challenge; retreatment

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Observational_studies / Risk_factors_studies Idioma: En Revista: Oncol Lett Año: 2018 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Grecia

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google